We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Proposes Extension of Biosimilar Review Times to Foster Discussion
FDA Proposes Extension of Biosimilar Review Times to Foster Discussion
The FDA is proposing to extend review times to enable more communication between the agency and sponsors to increase the number of first cycle approvals for biosimilars.